Target Name: CCNYL1
NCBI ID: G151195
Review Report on CCNYL1 Target / Biomarker Content of Review Report on CCNYL1 Target / Biomarker
CCNYL1
Other Name(s): Cyclin Y like 1, transcript variant 1 | Cyclin-Y-like protein 1 | Cyclin-Y-like protein 1 (isoform 1) | CCNYL1 variant 1 | CCYL1_HUMAN | cyclin Y like 1 | FLJ40432

CCNYL1: A Potential Drug Target and Biomarker for Cancer

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of individuals. The development of new treatments and biomarkers for cancer has become a major focus in the fight against this disease. Cyclin Y-like 1 (CCNYL1) is a protein that has been identified as a potential drug target and biomarker for cancer. In this article, we will explore the biology of CCNYL1, its potential as a drug target, and its potential as a biomarker for cancer.

Biography of CCNYL1

CCNYL1 is a 22-kDa protein that is expressed in various tissues and cells, including the brain, pancreas, and gastrointestinal tract. It is a key component of the cell cycle, specifically the G1 phase of the cell cycle. CCNYL1 plays a critical role in regulating the progression of the cell cycle by preventing the entry of the G2 phase and the metaphase-anaphase transition (G2/M transition).

CCNYL1 has been shown to be involved in various cellular processes, including cell growth, apoptosis, and autophagy. It has also been shown to be involved in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancers (2 ).

Potential Drug Target

The potential drug target for CCNYL1 is based on its role in the cell cycle and its involvement in the development and progression of cancer. Drugs that target CCNYL1 have the potential to inhibit its activity in the cell cycle, leading to the inhibition of cell growth and the inhibition of the development and progression of cancer.

One class of drugs that have been shown to target CCNYL1 is the taxane-based chemotherapy drugs, such as tamoxifen and rizatinib. These drugs work by inhibiting the activity ofCCNYL1 and preventing the entry of the G2 phase and the metaphase-anaphase transition (G2/M transition).

Another class of drugs that have been shown to target CCNYL1 are the small molecule inhibitors, such as inhibitors of the DNA replication complex, including NEDD8 and HDACs. These drugs work by inhibiting the activity ofCCNYL1 and preventing the entry of the G2 phase and the metaphase -anaphase transition (G2/M transition).

Potential Biomarkers

CCNYL1 has also been shown to be a potential biomarker for cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that CCNYL1 has been associated with the poor prognosis of cancer patients, with higher levels of CCNYL1 expression being associated with poor prognosis.

In conclusion, CCNYL1 is a protein that has been identified as a potential drug target and biomarker for cancer. Its role in the cell cycle and its involvement in the development and progression of cancer make it an attractive target for new treatments. Further research is needed to fully understand the biology of CCNYL1 and its potential as a drug target and biomarker for cancer.

Protein Name: Cyclin Y Like 1

The "CCNYL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCNYL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT